Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Lett. 2011 Feb 1;301(1):47-56. doi: 10.1016/j.canlet.2010.10.026. Epub 2010 Nov 19.

Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells.

Author information

  • 1Hospital Universitario San Cecilio, Granada, Spain. jamg@ugr.es

Abstract

The purpose of this study was to investigate whether PARP-1 inhibition sensitizes human liver cancer cell lines to doxorubicin treatment. Both the addition of PARP-1 inhibitor (ANI) and depletion by means of stable siRNA significantly enhanced the growth inhibition induced by the DNA damage agents used. This effect was associated with an accumulation of unrepaired DNA, with a reduction in EGFR and Bcl-xL gene expression as well as with positive annexin-V staining. These results provide novel evidence of the direct role of PARP-1 in tumour chemoresistance in relation to its effects on the transcription of key genes involved in tumour survival.

PMID:
21093979
DOI:
10.1016/j.canlet.2010.10.026
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center